Previous close | 0.4000 |
Open | 0.4000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.50 |
Expiry date | 2024-06-21 |
Day's range | 0.4000 - 0.4000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson’s diseaseBETHESDA, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late-breaking abstract with new data on GT-02287 has been accepted for presentation
BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended March 31, 2024, and provides a corporate update. Corporate Highlights from Q1 2024 to Date Announced Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial o
Gain Therapeutics (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.